Might also be noteworthy that the motley fool states that some analysts are predicting that Lenti-D approval could bring 4 billion! Now, you don’t think that the forgotten about jv could be with bluebird do you? Or... could it be more sinister in that bluebird is trying to squash any potential competition?
REGARDING THE PATENT RENEWAL ASSIGNED TO HAROLD RUMPH AND PAUL REID: THEY ARE THE SCIENTISTS THAT WORKED FOR NUTRA PHARMA'S RECEPTOPHARM, THEN SUED RICK AND SETTLED; SOME SAY THEY ARE BEHIND THE PRODUCT NAMED COBRAZOL, VERY SIMILAR TO NYLOXIN AND SOLD SUCCESFULLY ON AMAZON.